Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
J Eur Acad Dermatol Venereol ; 25(3): 276-84, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20626536

RESUMO

BACKGROUND: Actinic cheilitis (AC) represents the equivalent of actinic keratosis on the lip. Various treatment modalities are available and the efficacy of diclofenac in hyaluronic acid has recently been described. Reflectance confocal microscopy (RCM) is a non-invasive imaging technique which has recently been applied for the diagnosis of actinic keratoses. Herein, we describe the applicability of RCM for the diagnosis of AC and for monitoring of treatment response of AC to diclofenac in hyaluronic acid. METHODS: Ten Caucasian patients with clinical suspicion for AC were included in this study. To obtain a non-invasive diagnosis, RCM was performed at baseline, followed by biopsy and respective confocal-histopathological correlation. Six patients with a histological diagnosis of AC were treated with diclofenac in hyaluronic acid, whereby monitoring was performed by RCM. RESULTS: Reflectance confocal microscopy was able to correctly identify 6/7 cases of AC and 3/3 cases of benign lesions. The most important RCM criteria for diagnosis of AC were cellular atypia at the stratum spinosum and granulosum with atypical honeycomb pattern. One patient with AC was misclassified as inflammatory cheilitis by RCM as it showed marked inflammatory response and lacked clear signs of cellular atypia on RCM imaging. Following topical treatment with diclofenac gel, 5/6 patients (83%) showed a good treatment response with regression of dysplasia on consecutive RCM examination. CONCLUSIONS: Reflectance confocal microscopy is a promising tool for the non-invasive diagnosis and monitoring of actinic cheilitis. However, marked inflammation represents a potential diagnostic pitfall. In this regard, biopsy should be performed in doubtful cases.


Assuntos
Microscopia Confocal/métodos , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios não Esteroides/uso terapêutico , Biópsia , Queilite/diagnóstico , Queilite/tratamento farmacológico , Queilite/patologia , Diagnóstico Diferencial , Diclofenaco/uso terapêutico , Feminino , Humanos , Leucoplasia/diagnóstico , Leucoplasia/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
3.
Dermatology ; 220(1): 15-24, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-19907131

RESUMO

BACKGROUND: Actinic keratoses (AK) represent cutaneous carcinoma in situ and have previously been evaluated by reflectance confocal microscopy (RCM). Treatment of AK with imiquimod (IMIQ) 5% cream has been shown to 'highlight' subclinical lesions. OBJECTIVE: The aim of this study was to test the applicability of RCM for noninvasive monitoring of actinic field cancerization and detection of subclinical AK. SUBJECTS AND METHODS: AK and surrounding skin sites with no apparent AK of 11 volunteers were selected for imaging and subsequently classified as 'clinical' and 'subclinical' AK. IMIQ was used 3 times weekly for 4 weeks. RESULTS: RCM was able to detect morphologic features of AK in both clinical and subclinical AK; features were more pronounced in clinical lesions. The immunomodulatory response induced by IMIQ was visualized by RCM. CONCLUSION: Our findings indicate that RCM allows noninvasive monitoring of treatment response in vivo and permits early detection of subclinical AK, thus substantiating the incentive for therapy.


Assuntos
Aminoquinolinas/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma in Situ/tratamento farmacológico , Monitoramento de Medicamentos/métodos , Ceratose Actínica/tratamento farmacológico , Microscopia Confocal/métodos , Idoso , Carcinoma in Situ/patologia , Humanos , Imiquimode , Ceratose Actínica/patologia , Pessoa de Meia-Idade , Resultado do Tratamento
4.
Br J Dermatol ; 157 Suppl 2: 18-20, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18067626

RESUMO

Actinic keratosis is a UV light-induced lesion and develops mostly in fair-skinned patients being susceptible to solar damage. The term actinic keratosis (AK) describes clinically ill-defined reddish to reddish-brown scaly lesions on erythematous base in areas damaged severely by sunlight. The term does not imply anything about the biology or histopathology. Actinic keratoses (AKs) have been recognized as precursor of cancer or of precancerous lesions in the past but today they are considered as an early in situ squamous cell carcinoma (1,2) and are categorized in several classifications with subdivisions into three grades depending on the amount of atypical keratinocytes in the epidermis.(3-6) The incidence of development of AK in caucasians increases with age, proximity to the equator and outdoor occupation. Australia has the highest skin cancer rate in the world. AKs are discovered in up to 40-50% of the Australian population older than 40 years.(7) AKs are the most common malignant lesion of the skin.(8-12).


Assuntos
Carcinoma de Células Escamosas/patologia , Ceratose/patologia , Neoplasias Induzidas por Radiação/patologia , Neoplasias Cutâneas/patologia , Carcinoma de Células Escamosas/etiologia , Humanos , Ceratose/etiologia , Neoplasias Cutâneas/etiologia , Raios Ultravioleta/efeitos adversos
5.
Br J Dermatol ; 157 Suppl 2: 34-40, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18067630

RESUMO

BACKGROUND: Actinic keratoses (AK) frequently occur on sun-exposed skin and are considered as in situ squamous cell carcinoma. To date, no treatment algorithm exists for first or second line therapies due to the lack of comparative studies. OBJECTIVE: This study compared the initial and 12-month clinical clearance, histological clearance, and cosmetic outcomes of topically applied 5% imiquimod (IMIQ) cream, 5% 5-fluorouracil (5-FU) ointment and cryosurgery for the treatment of AK. PATIENTS/METHODS: Patients were randomised to one of the following three treatment groups: one or two courses of cryosurgery (20-40 s per lesion), topical 5-FU (twice daily for 4 weeks), or one or two courses of topical imquimod (three times per week for 4 weeks each). RESULTS: Sixty-eight per cent (17/25) of patients treated with cryosurgery, 96% (23/24) of patients treated with 5-FU, and 85% (22/26) of patients treated with IMIQ achieved initial clinical clearance, p = 0.03. The histological clearance rate for cryosurgery was 32% (8/25), 67% (16/24) for 5-FU, and 73% (19/26) in the IMIQ group, p = 0.03. The 12-month follow-up showed a high rate of recurrent and new lesions in the 5-FU and cryosurgery arms. The sustained clearance rate of initially cleared individual lesions was 28% (7/25) for cryosurgery, 54% (13/24) for 5-FU and 73% (19/26) for IMIQ (p < 0.01). Sustained clearance of the total treatment field was 4% (1/25), 33% (8/24), and 73% (19/26) of patients after cryosurgery, 5-FU, and IMIQ, respectively (p < 0.01). The patients in the IMIQ group were judged to have the best cosmetic outcomes (p = 0.0001). CONCLUSION: Imiquimod treatment of AK resulted in superior sustained clearance and cosmetic outcomes compared with cryosurgery and 5-FU. It should be considered as a first line therapy for sustained treatment of AK.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Criocirurgia , Ceratose/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Aminoquinolinas/efeitos adversos , Aminoquinolinas/uso terapêutico , Antineoplásicos/efeitos adversos , Carcinoma de Células Escamosas/cirurgia , Criocirurgia/efeitos adversos , Estética , Feminino , Fluoruracila/efeitos adversos , Fluoruracila/uso terapêutico , Seguimentos , Humanos , Imiquimode , Imunocompetência , Masculino , Pessoa de Meia-Idade , Neoplasias Induzidas por Radiação/tratamento farmacológico , Neoplasias Induzidas por Radiação/cirurgia , Neoplasias Cutâneas/cirurgia , Resultado do Tratamento , Raios Ultravioleta/efeitos adversos
6.
Br J Dermatol ; 157 Suppl 2: 47-51, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18067632

RESUMO

Basal cell carcinoma (BCC) is a malignant epithelial neoplasm of the skin preferentially affecting male caucasians and is rarely observed in patients with more intense skin pigmentation. A characteristic feature of BCCs are their extremely low risk to metastasize. Epidemiological data indicate that the overall incidence is increasing worldwide significantly by about 3-10% per annum.(1-3) Based on the increasing incidence of this usually not life-threatening tumour BCC appears to develop into a growing public health problem. This review elucidates the risk factors for the development and for the progression of BCC leading to an improved understanding of this tumour.


Assuntos
Carcinoma Basocelular/epidemiologia , Neoplasias Cutâneas/epidemiologia , Carcinoma Basocelular/etiologia , Carcinoma Basocelular/patologia , Progressão da Doença , Humanos , Fatores de Risco , Neoplasias Cutâneas/etiologia , Neoplasias Cutâneas/patologia
7.
Br J Dermatol ; 157 Suppl 2: 56-8, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18067634

RESUMO

Minimally invasive diagnostic tools have received increased attention for diagnosis, screening and management of nonmelanoma skin cancer (NMSC). Several modalities are commercially available, including high frequency ultrasound, optical coherence tomography and confocal microscopy. While systematic clinical analyses are often lacking, recent reports have shown promising results for reflectance confocal microscopy (RCM) for diagnosis of actinic keratoses and basal cell carcinoma.


Assuntos
Neoplasias Cutâneas/diagnóstico , Carcinoma Basocelular/diagnóstico , Carcinoma de Células Escamosas/diagnóstico , Diagnóstico Diferencial , Humanos , Ceratose/diagnóstico , Microscopia Confocal , Neoplasias Induzidas por Radiação/diagnóstico , Raios Ultravioleta/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...